
MLN Matters Number: MM12049
Related CR Release Date: November 20, 2020
Related CR Transmittal Number: R10470OTN

Related Change Request (CR) Number: 12049
Effective Date: Claims received on or after February 1, 2021
Implementation Date: February 22, 2021

PROVIDER TYPES AFFECTED

This MLN Matters Article is for physicians, providers, and suppliers submitting claims to Medicare Administrative Contractors (MACs) for services provided to Medicare beneficiaries.

PROVIDER ACTION NEEDED

This article informs you about two newly created condition codes:

- “90” – To allow providers to report when the service is provided as part of an Expanded Access approval
- “91” – To allow providers to report when the service is provided as part of an Emergency Use Authorization (EUA)

Please make sure your billing staffs are aware of these updates. These codes are effective for claims received on or after February 1, 2021.

BACKGROUND

Since the 1970s, the United States Food & Drug Administration (FDA) has made investigational drugs available to patients with serious diseases or conditions when there is no comparable satisfactory alternative therapy to diagnose, monitor, or treat that patient’s disease or condition. The FDA formalized this Expanded Access (EA) process in 1987 for drugs and biologics through 21 Code of Federal Regulations (CFR) 312 Section I. In 1996, the FDA formalized the process for devices via 21 CFR Part 812. EA was further codified in law in 1997. The FDA’s EA program is sometimes referred to as the “compassionate use” program. “Expanded access”
involves use of an investigational medical product outside of a clinical trial.

The EA program provides a process for patients to obtain authorization to use an investigational medical product for treatment use that has not been FDA approved for use outside of clinical trial settings per the Food and Drug Administration Modernization Act of 1997 (FDAMA).

In this context, “approved” or “approval” refers to the following:
- Approval for a drug or device
- Licensing for a biologic
- Marketing authorization for a medical device via the premarket approval, 510(k) or De Novo classification pathway
- For a medical device that is exempt from premarket notification to be marketed in the United States.

Providers shall append the newly created condition code 90 to claims with Expanded Access (EA) services.

The EUA authority allows the FDA to help strengthen the nation’s public health protections against Chemical, Biological, Radiological, and Nuclear (CBRN) threats by making available the use of Medical Countermeasures (MCMs) needed during Public Health Emergencies (PHEs).

Section 564 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) permits the FDA Commissioner to allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by CBRN threat agents when there are no adequate, approved, and available alternatives.

Section 564 of the FD&C Act was amended by the Project Bioshield Act of 2004 and was further amended by the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 (PAHPRA), the 21st Century Cures Act of 216, and Public Law 115-92 of 2017.

A determination under Section 319 of the Public Health Service Act that a PHE exists, such as the one issued on January 31, 2020, does not enable FDA to issue EUAs. A separate determination and declaration are needed under Section 564 of the FD&C Act to enable the FDA to issue EUAs, provided other statutory criteria are met.

Providers shall append the newly created condition code 91 to claims with Emergency Use Authorization (EUA) services.

CR 12049 does not implement any new policy. Usage of condition codes 90 or 91 do not affect coverage of services. Providers shall continue to follow Medicare billing and coverage guidelines for services billed to the Medicare program.
ADDITIONAL INFORMATION


If you have questions, your MACs may have more information. Find their website at [http://go.cms.gov/MAC-website-list](http://go.cms.gov/MAC-website-list).

DOCUMENT HISTORY

<table>
<thead>
<tr>
<th>Date of Change</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>November 20, 2020</td>
<td>Initial article released.</td>
</tr>
</tbody>
</table>

Disclaimer: Paid for by the Department of Health & Human Services. This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2019 American Medical Association. All rights reserved.

Copyright © 2013-2020, the American Hospital Association, Chicago, Illinois. Reproduced by CMS with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816. You may also contact us at ub04@healthforum.com

The American Hospital Association (the “AHA”) has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.